Tactic Links - Organic Traffic Booster - Home

Path: Home > List > Load (viennabiocenter.org)

domain	viennabiocenter.org
summary	Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for high-growth preventive vaccines markets, has announced that it has entered into a collaboration agreement with Pfizer Inc., to co-develop and commercialize a recombinant Lyme disease vaccine candidate using Valneva’s VLA15 and Pfizer's BP528 adjuvant. The collaboration combines the expertise of both companies, including Valneva's experience in Lyme disease vaccinology, manufacturing, and clinical development and Pfizer's extensive experience in vaccine adjuvants and the commercialization of vaccines globally. "We are excited to be collaborating with Pfizer on the development of a Lyme disease vaccine," said Thomas Lingelbach, MD, PhD, President and CEO at Valneva. "The collaboration will bring together our leading Lyme disease vaccine candidate with Pfizer's proven adjuvant technology, in an effort to develop a best-in-class prophylactic Lyme disease vaccine for the prevention of this significant public health concern." Valneva and Pfizer plan to initiate a Phase 1 clinical trial in healthy volunteers in the first half of 2021. The Phase 1 clinical trial will evaluate the safety, tolerability, immunogenicity, and dose selection of VLA15 in combination with BP528 adjuvant. "We are pleased to be working with Valneva on this important collaboration," said Bill Rosen, M.D., Ph.D., Chief Scientific Officer, Infectious Diseases at Pfizer Inc. "Lyme disease continues to pose a serious public health challenge in many parts of the world. This collaboration leverages Pfizer's expertise and our extensive experience in developing successful vaccines, including the recent FDA approval of our Prevnar 20 vaccine for adults." Valneva believes that there is significant potential for the Lyme disease vaccine market globally. In the United States alone, more than 300,000 cases are reported annually to CDC and Lyme disease is the most common vector-borne illness in the country. The global Lyme disease market was estimated at $2.5 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of approximately 6% between 2019 and 2026, according to a Grand View Research report. The collaboration agreement grants Pfizer an exclusive license to commercialize the Lyme disease vaccine candidate in all countries outside of Valneva's core markets, which include France, Germany, Italy, Spain, Austria, Switzerland, Canada, and the United States. In addition, Valneva will receive an upfront payment from Pfizer and is eligible to receive milestone payments upon achievement of certain development, regulatory, and sales-based milestones, as well as tiered royalties on net sales of the vaccine.
title	Homepage \| Vienna BioCenter \| Leading life science cluster
description	Vienna BioCenter offers a unique combination of research, education and companies. Leader in life sciences. Find out about our campus, our jobs and more!
keywords	vaccine, vienna, page, link, research, candidate, phase, perutz, award, scientists, cell, more, data, disease, reports, life, back
upstreams
downstreams
nslookup	A 5.132.161.194
created	2025-08-24
updated	2025-09-01
summarized	2025-09-01

HIGHSPOTS
tacticlinks.com
lhapsus.xyz
cluebit.com
greenpeace.org
escrache.org